Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.7%. By the end of trading, Amgen rose $2.00 (2.1%) to $98.28 on heavy volume. Throughout the day, 6,248,163 shares of Amgen exchanged hands as compared to its average daily volume of 3,846,300 shares. The stock ranged in a price between $95.06-$99.12 after having opened the day at $97.08 as compared to the previous trading day's close of $96.28. Other companies within the Health Care sector that increased today were:
), up 25.6%,
), up 22.0%,
), up 21.5% and
), up 18.9%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $74.4 billion and is part of the drugs industry. The company has a P/E ratio of 16.8, below the S&P 500 P/E ratio of 17.7. Shares are up 11.7% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.
- You can view the full Amgen Ratings Report.
On the negative front,
), down 64.8%,
), down 30.7%,
), down 17.4% and
), down 16.7% , were all laggards within the health care sector with
) being today's health care sector laggard.
- Use our health care section to find sector-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider
) while those bearish on the health care sector could consider
- Find other investment ideas from our top rated ETFs lists.
3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.